Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel S Childs

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Prostate Cancer and Prostatic Diseases|November 7, 2023
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancerMohamed E Ahmed, Matthew S Lee, Ahmed M Mahmoud, et al.
JAMA Oncology|March 2, 2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, et al.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Cancers|September 27, 2025
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA TestingMiguel Muniz, L Jill Tsai, Jacob J Orme, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [<sup>177</sup>Lu]Lu-PSMA-617Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
BJU International|November 30, 2024
In-field prostate cancer recurrence following radical prostatectomy and salvage radiationAustin Martin, Ahmed M Mahmoud, Cameron J Britton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancers|June 19, 2024
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic StrategiesAhmed M Mahmoud, Amr Moustafa, Carter Day, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Prostate Cancer and Prostatic Diseases|November 7, 2023
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancerMohamed E Ahmed, Matthew S Lee, Ahmed M Mahmoud, et al.
JAMA Oncology|March 2, 2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, et al.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Cancers|September 27, 2025
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA TestingMiguel Muniz, L Jill Tsai, Jacob J Orme, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [<sup>177</sup>Lu]Lu-PSMA-617Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
BJU International|November 30, 2024
In-field prostate cancer recurrence following radical prostatectomy and salvage radiationAustin Martin, Ahmed M Mahmoud, Cameron J Britton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancers|June 19, 2024
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic StrategiesAhmed M Mahmoud, Amr Moustafa, Carter Day, et al.
Pageof 6